INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
07/14/2026
Back to search
Official data from USPTO
HYFC TECHNOLOGY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
07/14/2026
Trademark type
Combined
Nice classes
5
Filing date
02/28/2018
Registration date
04/30/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/14/2025
Last transaction
07/14/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
KR
Examiner
EISNACH, MICHAEL PATRICK
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized design consisting of two ovals connected by 5 lines to two more ovals that are divided, and are stacked above two other ovals. To the right of the stylized design are the letters "hyFc" stacked above the word "technology".
Holders and representatives
Holders
Genexine, Inc.
Representatives
Diane J. Mason Drinker Biddle & Reath LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; pharmaceutical preparations for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of infectious diseases; Synthetic peptides for pharmaceutical purposes for treating hypertension; Synthetic peptides for pharmaceutical purposes for the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of hormonal disorders and the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of eye diseases and conditions; Synthetic peptides for pharmaceutical purposes for the treatment of multiple sclerosis; Synthetic peptides for pharmaceutical purposes for treating diabetes; Synthetic peptides for pharmaceutical purposes for affecting metabolism; Synthetic peptides for pharmaceutical purposes for regulating the immune system; Synthetic peptides for pharmaceutical purposes for the treatment of viral diseases; Synthetic peptides for pharmaceutical purposes for affecting and treating urogenital organs; Synthetic peptides for pharmaceutical purposes for preventing and treating obesity; Synthetic peptides for pharmaceutical purposes for the treatment of bone diseases; Synthetic peptides for pharmaceutical purposes for wounds; Synthetic peptides for pharmaceutical purposes for activating cellular function; Synthetic peptides for pharmaceutical purposes for affecting digestive organs; Synthetic peptides for pharmaceutical purposes for the treatment of cardiovascular disease; Synthetic peptides for pharmaceutical purposes for treating malignant tumours; Synthetic peptides for pharmaceutical purposes for the treatment and prevention of cancer; Synthetic peptides for pharmaceutical purposes for treatment of viral and infectious diseasesfor the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of auto-immune diseases
Publications
History of USPTO decisions and trademark events.
32 publications found
C71T
CANCELLED SECTION 71
11/14/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/07/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/28/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/30/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/28/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/13/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/24/2019
FIMP
FINAL DISPOSITION PROCESSED
08/24/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/30/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/13/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
04/30/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/12/2019
PUBO
PUBLISHED FOR OPPOSITION
02/12/2019
GPNX
NOTIFICATION PROCESSED BY IB
02/08/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/23/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/23/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/23/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/28/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/27/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/27/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/27/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/27/2018
RFNT
REFUSAL PROCESSED BY IB
07/14/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/28/2018
RFRR
REFUSAL PROCESSED BY MPU
06/28/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/20/2018
CNRT
NON-FINAL ACTION WRITTEN
06/19/2018
DOCK
ASSIGNED TO EXAMINER
06/12/2018
MAFR
APPLICATION FILING RECEIPT MAILED
06/05/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/01/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/24/2018
Continuous trademark protection
Get notified about every new filing that threatens HYFC TECHNOLOGY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.